----

----

|  Colorado                                                                  |   |  84-1509950                             |
|--------------------------------------------------------------------------------------|--------|----------------------------------------------|
| (State or      other jurisdiction of      incorporation or organization)   |   |  (IRS Employer      Identification No.) |

----

|                                                                                 |                                                                                         | PageNumber     |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------|
| PART      I.                                                                         | FINANCIAL      INFORMATION                                                                   |           |
|                                                                                 |                                                                                         |           |
| Item      1.                                                                         | Consolidated      Financial Statements                                                       |           |
|                                                                                 |                                                                                         |
|     Consolidated      Balance Sheets                             |        3-4                                                                              |
|                                                                                 |                                                                                         |
|     Consolidated      Statements of Operations                   |        5                                                                                |
|                                                                                 |                                                                                         |
|     Consolidated      Statements of Cash Flows                   |        6                                                                                |
|                                                                                 |                                                                                         |
|     Consolidated      Statements of Comprehensive Loss           |        7                                                                                |
|                                                                                 |                                                                                         |
|     Consolidated      Statement of Stockholders’ (Deficit) |        8                                                                                |
|                                                                                 |                                                                                         |           |
|     Notes      to Unaudited Consolidated Financial Statements    |        9                                                                                |
|                                                                                 |                                                                                         |
| Item      2.                                                                         | Management's      Discussion and Analysis of Financial      Condition and Plan of Operations |        13 |
|                                                                                 |                                                                                         |
| Item      3.                                                                         | Quantitative      and Qualitative Disclosures about Market Risk                              |
|                                                                                 |        16                                                                               |
| Item      4.                                                                         | Controls      and Procedures                                                                 |           |
|                                                                                 |        16                                                                               |
| Part      II.                                                                        | OTHER      INFORMATION                                                                       |           |
|                                                                                 |                                                                                         |
| Item      1.                                                                         | Legal      proceedings                                                                       |           |
|                                                                                 |                                                                                         |        16 |
| Item      1A.                                                                        | Risk      Factors                                                                            |           |
|                                                                                 |                                                                                         |
| Item      2.                                                                         | Unregistered      Sales of Equity Securities and Use of Proceeds                             |        17 |
|                                                                                 |                                                                                         |           |
| Item      3.                                                                         | Defaults      upon Senior Securities                                                         |        17 |
|                                                                                 |                                                                                         |
| Item      4.                                                                         | Submission      of Matters to a Vote of Security Holders                                     |        17 |
|                                                                                 |                                                                                         |
| Item      5.                                                                         | Other      Information                                                                       |        17 |
|                                                                                 |                                                                                         |
| Item      6.                                                                         | Exhibits      and Reports of Form 8-K                                                        |        17 |
|                                                                                 |                                                                                         |
| SIGNATURES                                                                           |        18                                                                               |

----

| Medical International      Technology, Inc.      |  Quarterly Financial      Report |
|---------------------------------------------------------------------------|---------------------------------------|

|                                                                                   |   | June      30, 2008 |     |   | Septemeber      30,2007 |   |
|----------------------------------------------------------------------------------------|--------|--------------------|----------|--------|-------------------------|--------|
|                                                                                   |   | (Unaudited)        |     |   | (Audited)               |   |
| Assets                                                                                 |   |               |     |   |                    |   |
|                                                                                   |   |               |     |   |                    |   |
|   Current      Assets                                                        |   |               |     |   |                    |   |
|     Cash      and cash equivalents                                 |   | $                  | 199,043  |   |                    | $      | 187,536 |   |
|     Accounts      receivable                                       |   |               | ---      |   |                    |   | 6,937 |   |
|     Inventories                                                    |   |               | 188,900  |   |                    |   | 194,826 |   |
|     Research credit      receivable                                |   |               | 103,976  |   |                    |   | 127,718 |   |
|     Prepaid      expenses                                          |   |               | 2,796    |   |                    |   | 2,764 |   |
|                                                                                   |   |               |     |   |                    |   |   |   |
|     Total Current Assets                                           |   |               | 494,715  |   |                    |   | 519,781 |   |
|                                                                                   |   |               |     |   |                    |   |   |   |
|   Property and      Equipment                                                |   |               |     |   |                    |   |   |   |
|     Tooling      and machinery                                     |   |               | 228,599  |   |                    |   | 225,175 |   |
|     Furniture and      office equipment                            |   |               | 133,014  |   |                    |   | 133,014 |   |
|     Leasehold      improvements                                    |   |               | 22,163   |   |                    |   | 22,163 |   |
|                                                                                   |   |               | 383,776  |   |                    |   | 380,352 |   |
|                                                                                   |   |               |     |   |                    |   |   |   |
|     Less      accumulated depreciation                             |   |               | (286,655 | )      |                    |   | (245,536 | )  |
|                                                                                   |   |               | 97,121   |   |                    |   | 134,816 |   |
| Other      Assets                                                                      |   |               |     |   |                    |   |   |   |
|     Patents      (net accumulated amortization of $1,282 and $932) |   |               | 748      |   |                    |   | 1,098 |   |
|                                                                                   |   |               |     |   |                    |   |   |   |
|         Total      Assets                      |   | $                  | 592,584  |   |                    | $      | 655,695 |   |
|                                                                                   |   |               |     |   |                    |   |   |   |

----

| Medical International      Technology, Inc.      |  Quarterly Financial      Report |
|---------------------------------------------------------------------------|---------------------------------------|

|                                                                 |   | June      20, 2008 |       |    | September      30,2007 |   |
|----------------------------------------------------------------------|--------|--------------------|------------|---------|------------------------|--------|
|                                                                 |   | (Unaudited)        |       |    | (Audited)              |   |
| Liabilities      and Stockholders' Equity (Deficit)                  |   |               |       |    |                   |   |
|                                                                 |   |               |       |    |                   |   |
| Current      Liabilities                                             |   |               |       |    |                   |   |
|     Unearned      income                         |   | $                  | 1,366,246  |    |                   | $      | 7,494 |   |
|     Accounts      payable and accrued expenses   |   |               | 179,526    |    |                   |   | 298,152 |   |
|     Loans      payable - related parties         |   |               | ---        |    |                   |   | 49,696 |   |
|     Current      portion of long-term debts      |   |               | 12,407     |    |                   |   | 283,154 |   |
|                                                                 |   |               | 1,558,179  |    |                   |   | 638,496 |   |
|     Long-Term      Debts                         |   |               | 8,652      |    |                   |   | 14,261 |   |
|                                                                 |   |               |       |    |                   |   |   |   |
|                                                                 |   |               |       |    |                   |   |   |   |
|                                                                 |   |               |       |    |                   |   |   |   |
| Total      Liabilities                                               |   |               | 1,566,831  |    |                   |   | 652,757 |   |
|                                                                 |   |               |       |    |                   |   |   |   |
| Stockholders'      Equity (Deficit)                                  |   |               |       |    |                   |   |   |   |
| Preferred      stock, $.0001 par value; 3,000,000 shares authorized; |   |               |       |    |                   |   |   |   |
| None      issued and outstanding as of June 30, 2008                 |   |               |       |    |                   |   |   |   |
|                                                                 |   |               |       |    |                   |   |   |   |
| Common      stock, $.0001 par value; 100,000,000 shares authorized;  |   |               |       |    |                   |   |   |   |
| Issued      and outstanding 27,058,663 shares as of June 30, 2008    |   |               | 2,706      |    |                   |   | 2,706 |   |
|                                                                 |   |               |       |    |                   |   |   |   |
| Additional      paid-in capital                                      |   |               | 6,804,339  |    |                   |   | 6,804,339 |   |
| Deficit                                                              |   |               | (7,672,565 | )  |                   |   | (6,971,531 | )  |
| Other      comprehensive income (loss)                               |   |               | (108727    | )  |                   |   | 167,424 |   |
|                                                                 |   |               |       |    |                   |   |   |   |
| Total      Stockholders' Equity (Deficit)                            |   |               | (974,247   | )  |                   |   | 2,938 |   |
|                                                                 |   |               |       |    |                   |   |   |   |
|                                                                 |   |               |       |    |                   |   |   |   |
| Total      Liabilities and Stockholders' Equity (Deficit)            |   | $                  | 592,584    |    |                   | $      | 655,695 |   |
|                                                                 |   |               |       |    |                   |   |   |   |

----

| Medical International      Technology, Inc.      |  Quarterly Financial      Report |
|---------------------------------------------------------------------------|---------------------------------------|

|                                               |   | Three-Months      EndedJune      30, |       |   | Nine-Months      Ended June      30, |   |
|----------------------------------------------------|--------|--------------------------------------|------------|--------|-------------------------------------------|--------|
|                                               |   | 2008(Unaudited)                      |       |   | 2007(Unaudited)                           |   |   | 2008(Unaudited) |   |   | 2007(Unaudited) |   |
|                                               |   |                                 |       |   |                                      |   |   |   |   |   |   |   |   |   |   |   |
| Sales                                              |   | $                                    | 140,553    |   |                                      | $      | 43,020 |   |   | $ | 306,060 |   |   | $ | 150,630 |   |
| Cost      of sales                                 |   |                                 | 37,655     |   |                                      |   | 5,778 |   |   |   | 136,986 |   |   |   | 58,151 |   |
| Gross      profit (loss)                           |   |                                 | 102,898    |   |                                      |   | 37,242 |   |   |   | 169,074 |   |   |   | 92,479 |   |
|                                               |   |                                 |       |   |                                      |   |   |   |   |   |   |   |   |   |   |   |
| Research      and development costs                |   |                                 | (78,990    | )      |                                      |   | 68,097 |   |   |   | 102,063 |   |   |   | 126,255 |   |
| Selling,      general, and administrative expenses |   |                                 | 427,268    |   |                                      |   | 136,343 |   |   |   | 763,372 |   |   |   | 508,407 |   |
|                                               |   |                                 | 348,278    |   |                                      |   | 204,440 |   |   |   | 865,435 |   |   |   | 634,662 |   |
|                                               |   |                                 |       |   |                                      |   |   |   |   |   |   |   |   |   |   |   |
|  Loss      from operations                    |   |                                 | (245,380   | )      |                                      |   | (167,198 | ) |   |   | (696,361 | ) |   |   | (542,184 | ) |
|                                               |   |                                 |       |   |                                      |   |   |   |   |   |   |   |   |   |   |   |
| Other      Income (Expense)                        |   |                                 |       |   |                                      |   |   |   |   |   |   |   |   |   |   |   |
| Interest      income                               |   |                                 | 152        |   |                                      |   | --- |   |   |   | 12,419 |   |   |   | --- |   |
| Interest      expense                              |   |                                 | (975       | )      |                                      |   | (45,989 | ) |   |   | (17,092 | ) |   |   | (56,812 | ) |
|                                               |   |                                 | ( 823      | )      |                                      |   | (45,989 | ) |   |   | (4,673 | ) |   |   | (56,812 | ) |
|                                               |   |                                 |       |   |                                      |   |   |   |   |   |   |   |   |   |   |   |
| Net      Loss                                      |   | $                                    | (246,203   | )      |                                      | $      | (213,187 | ) |   | $ | (701,034 | ) |   | $ | (598,996 | ) |
|                                               |   |                                 |       |   |                                      |   |   |   |   |   |   |   |   |   |   |   |
| Basic      (loss) per share                        |   | $                                    | (0.009     | )      |                                      | $      | (0.012 | ) |   | $ | (0.02 | ) |   | $ | (0.03 | ) |
|                                               |   |                                 |       |   |                                      |   |   |   |   |   |   |   |   |   |   |   |
| Basic      weighted average shares outstanding     |   |                                 | 27,058,663 |   |                                      |   | 18,184,197 |   |   |   | 27,058,663 |   |   |   | 18,184,197 |   |
|                                               |   |                                 |       |   |                                      |   |   |   |   |   |   |   |   |   |   |   |

----

| Medical International      Technology, Inc.      |  Quarterly Financial      Report |
|---------------------------------------------------------------------------|---------------------------------------|

|                                                                                                |   | Nine-Months      Ended June 30, |      |
|-----------------------------------------------------------------------------------------------------|--------|---------------------------------|-----------|
|                                                                                                |   | 2008                            |      |   | 2007 |   |
|                                                                                                |   | (Unaudited)                |      |   | (Unaudited)  |   |
|                                                                                                |   |                            |      |   |   |   |
| Cash      Flows from Operating Activities                                                           |   |                            |      |   |   |   |
|   Net      Loss                                                                           |   | $                               | (701,034  | ) |   | $ | (598,997 | ) |
|   Adjustments to      reconcile net loss to net cash                                      |   |                            |      |   |   |   |   |   |
|    Used in      operating activities:                                                |   |                            |      |   |   |   |   |   |
|            Depreciation and amortization expense                           |   |                            | 41,468    |   |   |   | 33,208 |   |
|            Common stock issued for consulting and legal services           |   |                            | -         |   |   |   | 369,559 |   |
|            Common stock issued for acquisition of SCANVIEW                 |   |                            | -         |   |   |   | 175,000 |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
|   (Increase) decrease      in Assets                                                      |   |                            |      |   |   |   |   |   |
|            (Increase) decrease in accounts receivable                      |   |                            | 6,937     |   |   |   | 14,232 |   |
|            Increase (decrease) in advances to related corporations         |   |                            | -         |   |   |   | -- |   |
|            (Increase) decrease in inventories                              |   |                            | 5,926     |   |   |   | (61,563 | )  |
|            (Increase) decrease in research tax credit receivable           |   |                            | 23,742    |   |   |   | 58,276 |   |
|            (Increase) decrease in prepaid expenses                         |   |                            | (32       | )  |   |   | (55,275 | )  |
|                                                                                                |   |                            |      |   |   |   |   |   |
|   Increase (decrease)      in Liabilities                                                 |   |                            |      |   |   |   |   |   |
|            Increase (decrease) in unearned income                          |   |                            | 1,358,752 |   |   |   | 31,756 |   |
|            Increase (decrease) in accounts payable and accrued    expenses |   |                            | (118,626  | )  |   |   | 71,919 |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
|            Net Cash Provided by (Used in) Operating Activities             |   |                            | 617,133   |   |   |   | 38,115 |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
| Cash      Flows from Investing Activities                                                           |   |                            |      |   |   |   |   |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
|       Equipment      acquisition                                      |   |                            | (3,423    | )  |   |   | (73,638 | )  |
|       Intangible      asset                                           |   |                            | -         |   |   |   | (131,382 | )  |
|                                                                                                |   |                            |      |   |   |   |   |   |
|            Net cash used in investing activities                           |   |                            | (3,423    | )  |   |   | (205,020 | )  |
|                                                                                                |   |                            |      |   |   |   |   |   |
| Cash      Flows from Financing Activities                                                           |   |                            |      |   |   |   |   |   |
|   Gross proceeds from      private offering                                               |   |                            | -         |   |   |   | 65,020 |   |
|   Reduction in      amounts due to related parties                                        |   |                            | (49,696   | )  |   |   | 100,092 |   |
|   Principal reduction      on small business loan                                         |   |                            | (276,356  | )  |   |   | - |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
|            Net Cash Provided by Financing Activities                       |   |                            | (326,052  | )  |   |   | 165,112 |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
| Effect      of exchange rates on cash                                                               |   |                            | (276,151  | )  |   |   | - |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
| Net      Increase (decrease) in Cash and Cash Equivalents                                           |   |                            | 11507     |   |   |   | (1,793 | )  |
|                                                                                                |   |                            |      |   |   |   |   |   |
| Beginning      Balance - Cash and Cash Equivalents                                                  |   |                            | 187,536   |   |   |   | 2,920 |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
| Ending      Balance - Cash and Cash Equivalents                                                     |   | $                               | 199,043   |   |   | $ | 1,127 |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
| Supplemental      Information:                                                                      |   |                            |      |   |   |   |   |   |
|                                                                                                |   |                            |      |   |   |   |   |   |
|       Cash      Paid For:                                                  |   |                            |      |   |   |   |   |   |
|       Interest      Expenses                                          |   | $                               | 17,092    |   |   | $ | 56,812 |   |
|       Income      Taxes                                               |   |                            | -         |   |   |   | - |   |

----

| Medical International      Technology, Inc.      |  Quarterly Financial      Report |
|---------------------------------------------------------------------------|---------------------------------------|

|                                         |   | Nine Months ending      June 30, 2008 |     |    | For the year ending September      30,2007 |   |
|----------------------------------------------|--------|---------------------------------------|----------|---------|--------------------------------------------|--------|
|                                         |   |                                  |     |    |                                       |   |
|                                         |   |                                  |     |    |                                       |   |
|                                         |   |                                  |     |    |                                       |   |
| Net      loss                                |   | $                                     | (701,034 | )       |                                       | $      | (898,376 | ) |
| Other      comprehensive income (loss)       |   |                                  |     |    |                                       |   |   |   |
| Foreign      currency translation adjustment |   |                                  | (108,728 | )  |                                       |   | 167,424 |   |
|                                         |   |                                  |     |    |                                       |   |   |   |
| Net      comprehensive income (loss)         |   | $                                     | (809,762 | )       |                                       | $      | (730,952 | ) |

----

| Medical International      Technology, Inc.      |  Quarterly Financial      Report |
|---------------------------------------------------------------------------|---------------------------------------|

|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |
|------------------------------------------------------|--------|-------------------|------------|--------|--------------------|--------|--------|------------------|--------|--------|-----------|--------|
|                                                 |   |              |       |   |               |   |   |  Additional |   |   |      |   |
|                                                 |   | Common      Stock |       |   |  Paid      in |   |   |             |   |
|                                                 |   | Shares            |       |   | Amount             |   |   | Capital          |   |   | Deficit   |   |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |
| Balance      – September 30, 2007              |   |              | 27,058,663 |   |               | $      | 2,706  |             |   | $      | 6,804,339 |   |   | $ | (6,971,531 | )  |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |   |   |   |   |
| Net      loss for the period ended December 31, 2007 |   |              | -          |   |               |   | -      |             |   |   | -         |   |   |   | (173,274 | )  |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |   |   |   |   |
| Balance      –December 31, 2007                |   |              | 27,058,663 |   |               | $      | 2,706  |             |   | $      | 6,804,339 |   |   | $ | (7,144,805 | ) |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |   |   |   |   |
| Net      loss for the period ended March 31, 2008    |   |              | -          |   |               |   | -      |             |   |   | -         |   |   |   | (281,557 | )  |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |   |   |   |   |
| Balance      – March 31, 2008                  |   |              | 27,058,663 |   |               | $      | 2,706  |             |   |   | 6,804,339 |   |   | $ | (7,426,362 | ) |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |   |   |   |   |
| Net      loss for the period ended June 30, 2008     |   |              | -          |   |               |   | -      |             |   |   | -         |   |   |   | (246,203 | ) |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |   |   |   |   |
| Balance      –June 30, 2008                    |   |              | 27,058,663 |   |               | $      | 2,706  |             |   | $      | 6,804,339 |   |   | $ | (7,672,565 | )  |
|                                                 |   |              |       |   |               |   |   |             |   |   |      |   |   |   |   |   |

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|
|                                                    |                                  |
| Notes to Financial      Statements                      |
|                                                    |
|  (Unaudited)                                       |

|                 |   | June      30, |    |   | September      30, |   |
|----------------------|--------|---------------|---------|--------|--------------------|--------|
|                 |   | 2008          |    |   | 2007               |   |
| Raw      materials   |   | $             | 149,961 |   |               | $      | 159,697 |   |
| Work      in process |   |          | 31,997  |   |               |   | 13,376 |   |
| Finished      goods  |   |          | 6,942   |   |               |   | 21,753 |   |
| Total                |   | $             | 188,900 |   |               | $      | 194,826 |   |
|                 |   |          |    |   |               |   |   |   |

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|
|                                                    |                                  |
| Notes to Financial      Statements                      |
|                                                    |
|  (Unaudited)                                       |

|               |   | June      30, |    |    | September      30, |   |
|--------------------|--------|---------------|---------|---------|--------------------|--------|
|               |   | 2008          |    |    | 2007               |   |
| R&D      Costs |   | $             | 105,221 |    |               | $      | 163,712 |   |
| Less      Credit   |   |          | (3,157  | )  |               |   | (29,418 | )  |
|               |   | $             | 102,064 |    |               | $      | 134,294 |   |
|               |   |          |    |    |               |   |   |   |

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|
|                                                    |                                  |
| Notes to Financial      Statements                      |
|                                                    |
|  (Unaudited)                                       |

|                                                             |   | June      30, |    |    | September      30, |   |
|------------------------------------------------------------------|--------|---------------|---------|---------|--------------------|--------|
|                                                             |   | 2008          |    |    | 2007               |   |
|                                                             |   |          |    |    |               |   |
| Note      payable to a bank, bearing interest at prime plus 2.5% |   |          |    |    |               |   |
|   secured by      equipment, due July 21, 2010.        |   | $             | 16,392  |    |               | $      | 22,040 |   |
|                                                             |   |          |    |    |               |   |   |   |
| Note      payable to a bank, bearing interest at prime plus 3%   |   |          |    |    |               |   |   |   |
|   secured by      equipment, due August 28, 2008       |   |          | 4,667   |    |               |   | 25,375 |   |
|                                                             |   |          |    |    |               |   |   |   |
| Note      payable to an individual, unsecured and                |   |          |    |    |               |   |   |   |
| due      on demand                                               |   |          | -       |    |               |   | 250,000 |   |
|                                                             |   |          |    |    |               |   |   |   |
|                                                             |   | $             | 21,059  |    |               | $      | 297,415 |   |
|                                                             |   |          |    |    |               |   |   |   |
| Current      portion of long-term debt                           |   |          | (12,407 | )  |               |   | (283,154 | )  |
|                                                             |   |          |    |    |               |   |   |   |
| Long-term      debt                                              |   | $             | 8,652   |    |               | $      | 14,261 |   |
|                                                             |   |          |    |    |               |   |   |   |
| Scheduled      maturities of long-term debt are as follows:      |   |          |    |    |               |   |   |   |
| June      30, 2009                                               |   | $             | 12,407  |    |               |   |   |   |
| June      30, 2010                                               |   |          | 7,740   |    |               |   |   |   |
| July      31, 2010                                               |   |          | 912     |    |               |   |   |   |
|                                                             |   |          | 21,059  |    |               |   |   |   |
|                                                             |   |          |    |    |               |   |   |   |

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|
|                                                    |                                  |
| Notes to Financial      Statements                      |
|                                                    |
|  (Unaudited)                                       |

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|

execute its business plan.

the company is engaged in the following legalproceedings:

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|

----

| Medical International      Technology, Inc.   |  Quarterly Financial      Report |
|---------------------------------------------------------|---------------------------------------|